Johnson & Johnson (JNJ) is the third-largest player in the global knee implant market and the second-largest player in markets outside the United States.
Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]
Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]
On July 12, 2017, a US district court judge increased the penalties to be paid by Zimmer Biomet Holdings to Stryker related to its patent infringement case.
On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.
PRITX aims to invest in established companies that are either headquartered outside of the United States or whose main businesses are carried out outside the United States.
Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets.
Stryker registered ~$2.8 billion in revenue in 2Q16. Around 72% of this was generated by its US business, and the remainder came from international sales.
Zimmer Holdings acquired Biomet in June 2015 and formed Zimmer Biomet Holdings (ZBH). The acquisition established the combined company as the second-largest player in the orthopedics medical device market segment.
Zimmer Biomet (ZBH) is the leading provider of knee implants in the United States. It has approximately 40% market share, followed by Stryker, Johnson & Johnson, and Smith & Nephew.
From a NAV return standpoint, BIAHX stood third among its peers for the one-year period until March 15, 2016. Since the ECB announcement of stimulus measures, the fund is fifth.
